New Biosimilar approval (biologic generic) may save billions in costs for rheumatoid arthritis patients
The biosimilar adventure continues-Somewhat like generic medicines, A new biosimilar for infliximab or (Remicade) got the approval not from the FDA. What this means is that the medicine works to combat rheumatoid arthritis and Chrohn's disease, but costs much much less that the well-known brand.
The FDA approved a generic version of the widely prescribed depression and anxiety medicine, Lexapro (escitalopram).
A novel weight loss drug might become available. Qnexa (a combination of the existing drugs phentermine and controlled release topiramate) was presented to the FDA in July 2010 and was rejected.
Tafluprost (Zioptan) was approved by the FDA to help lower increased eye pressure in people suffering from open-angle glaucoma.